Robert C. Nowinski, Ph.D.
Biotech entrepreneur

Responsible for some of the most profitable drugs on the market today, Dr. Robert Nowinski is a biotechnology financier and consultant who has founded six pioneering biotech companies. In addition to acquiring initial technology for those companies, Dr. Robert Nowinski recruited top management, provided research oversight, brought startup financing to the table and ultimately took four of the companies public through IPO financing.

Proof of his success, major pharmaceutical companies have acquired three of the companies founded by Dr. Robert Nowinski. Bristol-Myers acquired Dr. Robert Nowinski’s Genetic Systems in 1987 for $310 million; Chiron/Novartis bought PathoGenesis in 2000 for $660 million; and Eli Lilly acquired Icos in 2006 for $2.2 billion. Collectively, Dr. Robert Nowinski’s companies have developed and marketed diagnostic tests and drugs with annual sales of more than $2.0 billion.

Research credentials
An accomplished researcher, Dr. Robert Nowinski earned his Ph.D. in immunology from the Sloan-Kettering Institute in 1971. From 1971 to 1975 he was an assistant professor of Oncology at the University of Wisconsin. From 1975 through 1981, Dr. Robert Nowinski was an associate professor of Microbiology and Immunology at the University of Washington.

Dr. Robert Nowinski was also a founding scientist and head of the Virology Program of the Fred Hutchinson Cancer Research Center, Seattle. From 1981 th